
UoH start-up claims breakthrough COVID treatment through stem cells
The Hindu
Significantly improved patient survival and time to recovery observed following the treatment, says Transcell Oncologics
A breakthrough human Umbilical Cord (UC) tissue harvested and clinically processed adult Mesenchymal Stem Cells (MSCs)-based therapy to COVID patients has been announced by Transcell Oncologics,a biotech start-up company, incubated at ASPIRE-Technology Business Incubator (ASPIRE-TBI), University of Hyderabad (UoH) on Monday. The firm had developed proprietary cell-based platform technology ‘HEMATO UC-MSCs’ with anti-cytokine storm properties, anti-inflammatory attributes and repairing abilities. The research recommends HEMATO UC-MSCs to be administered as “two intravenous infusions, at a dose of 100 million cells per infusion, given 72 hours apart to the COVID patients. “A significant decrease in a set of inflammatory cytokines involved in the COVID-19 “cytokine storm”; with significantly improved patient survival and time to recovery was observed following the treatment,” claimed, an official spokesman in a press release.More Related News

The draft policy for “Responsible Digital Use Among Students”, released on Monday by the Department of Health and Family Welfare, has recommended that parents set structured routines with clear screen-time rules and prioritise privacy, safety, and open conversation with children on digital well-being.












